Direct-acting antivirals for chronic hepatitis C treatment: The experience of two tertiary university centers in Brazil

Table 6 Factors associated with the occurrence of adverse events during treatment

Variable	Univariate analysis			Multivariate analysis
	OR	95%CI	P value	OR	95%CI	P value
Age	1.011	0.994-1.027	0.2086
Women	1.718	1.205-2.450	0.0028a	2.191	1.145-1.192	0.0178a
High-blood pressure	0.838	0.587-1.197	0.3315
Type 2 diabetes	0.994	0.675-1.461	0.9736
BMI	1.060	1.019-1.102	0.0040a	1.107	1.038-1.180	0.0020a
Dyslipidemia	0.714	0.458-1.114	0.1377
Hypothyroidism	0.971	0.603-1.565	0.9053
Psychiatric disorder	1.309	0.732-2.340	0.3633
Previous alcohol use	0.953	0.610-1.488	0.8307
Presence of cirrhosis	2.127	1.476-3.065	< 0.0001a
Liver-related complications
Ascites	2.187	1.352-3.536	0.0014a
Esophageal varices	2.795	1.874-4.169	< 0.0001a	3.463	1.688-7.105	0.0007a
Portal hypertensive bleeding	1.747	0.946-3.228	0.0749
Hepatic encephalopathy	3.524	1.762-7.044	0.0004a
AST	1.000	0.997-1.004	0.8303
ALT	0.999	0.996-1.002	0.4848
Total bilirubin	1.283	1.052-1.564	0.0138a
Albumin	0.432	0.314-0.595	< 0.0001a
INR	3.835	1.539-9.560	0.0039a	3.748	1.060-13.251	0.0403a
Creatinine	0.934	0.845-1.032	0.1818
Hemoglobin	0.951	0.866-1.044	0.2910
Alpha-fetoprotein	0.998	0.993-1.003	0.3656
Child-Pugh score	1.196	1.014-1.410	0.0332a
MELD score	1.071	1.019-1.126	0.0073a
Ribavirin dose	1.249	1.132-1.379	< 0.0001a
Treatment duration	1.071	1.034-1.109	0.0001a	1.062	1.003-1.125	0.0406a

^aP value < 0.05. Logistic regression. ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BMI: Body mass index; HCV: Hepatitis C virus; INR: International normalized ratio; MELD: Model for end-stage liver disease; OR: Odds ratio.